Enbrel 50 MG/ML sureclickml
Ended Awarded Last action
- Contract number
- SPE2DR26FQU6N
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $190,391
Award facts
- Contract value 100% obligated
- $190,390.84 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $190,390.84 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/mL SureClick auto-injectors. This firm fixed-price contract, issued on January 15, 2026, with completion scheduled for January 16, 2026, represents a non-set-aside procurement awarded through competitive procedures. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under a larger Indefinite Delivery Contract (IDC) vehicle—the DLA Troop Support Medical Pharmaceutical Prime Vendor Global Program—which is valued at up to $999,999,999.00 through December 2026 and serves as the comprehensive procurement mechanism for pharmaceutical products and medical supplies supporting military healthcare programs worldwide.
AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major pharmaceutical distributor and healthcare solutions provider specializing in supplying brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities to federal agencies. The company's extensive portfolio of federal contracts demonstrates its capability to meet competitive procurement requirements across multiple therapeutic domains. Enbrel is a biologic immunosuppressant used to treat autoimmune conditions and is a critical therapeutic medication within the military healthcare supply chain. This award reflects AmerisourceBergen's ongoing role as a strategic supplier to the Defense Health Agency and other federal healthcare systems through the DLA's pharmaceutical contracting programs.
Quick answers
Who was awarded contract SPE2DR26FQU6N?
SPE2DR26FQU6N was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 15, 2026.
How much is contract SPE2DR26FQU6N worth?
The government has obligated $190,391 on SPE2DR26FQU6N.
Is contract SPE2DR26FQU6N an order under another contract?
Yes. SPE2DR26FQU6N is a delivery order under SPE2DR25D1022, an indefinite delivery contract.
Was contract SPE2DR26FQU6N competed?
The extent of competition for SPE2DR26FQU6N was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award